Diagnostics

Thyrocare reported 23% YoY rise in revenue in December quarter

Vijaya Diagnostic Centre: Early success from new geographies reassuring

The company continues to expand beyond its legacy markets — Andhra and Tel-angana — to Pune, Gurugram, and Kolkata

Suraksha Diagnostics IPO: A play on eastern India healthcare demand

A successful replication of the business model outside the core area will be key to growth

Krsnaa Diagnostics: Expanding addressable market with a B2C foray

With the ramp-up of new projects, the current revenue growth trajectory should continue into FY25-26

Temasek and MOPE-backed Molbio Diagnostics kickstarts IPO prep, aims Rs 22,000-24,000 cr valuation

Molbio Diagnostics, which is known for its molecular diagnostics platform, became Goa's first startup to hit unicorn status in September 2022

Metropolis Healthcare to spend Rs 50-55 crore over two years to expand

The company has positioned itself as a premium diagnostics player. The premium wellness category was its fastest-growing segment in Q2

Diagnostics players have become rational in terms of pricing: Thyrocare CEO

Throcare had normalised EBITDA of 30 percent in Q2 of FY24 and in the same period the previous year.

As diagnostics price wars ease, some new-age holdouts keep up pressure on older rivals

Analysts said the race to the bottom seems to be over and there appears to be a clear shift in the sector, with prices increasing gradually

Diagnostic players shun discounts, opt for the premium route

Most new-age diagnostic players moved away from heavy discounts and are now raising prices. With this, the difference in pricing between incumbents and established players is narrowing and moving towards a level-playing field

Pharma deep dive: Not the time to buy hospitals, bullish on diagnostics, says Incred’s Khemka

Khemka also says there are many reasons unbranded generics won’t work in India.

Healthcare sector on robust growth path; here's why

Demand for wellness, better health awareness and greater access to medical facilities will drive the growth of all players in the healthcare industry and associated sectors.

Diagnostics: Time to look at this quasi-consumer industry

A bigger landscape of opportunity awaits organised diagnostic chains to increase market share

Highest risk, maximum reward in healthcare lies in diagnostics, says Incred PMS' Aditya Khemka

For investors in hospital stocks, Khemka says the right time for entry is when the company has completed its capex, because the downside potential from that level is less, while the upside is good.

Discovery Series: Krsnaa Diagnostics -- Multiple catalysts at work

Business fundamentals look solid and the growth potential is very promising

Lupin: Why you need to avoid despite improving US business

The improvement in both top line and margins are expected to be gradual

Redcliffe Labs lines up additional $10 million to expand operations

The company, which has a focus on next generation technologies in the diagnostics space after building an AI (artificial intelligence) platform, has already invested USD 6 million earlier into genetics and specialised testing coverage from prenatal to oncology, neurology and nephrology, among other segments.

Discovery series: Is it time to start looking at this quality diagnostic service?

We expect an earnings CAGR in mid-teens in the medium term for VDC on the back of an expansion-led volume growth in the hinterland

Online diagnostic firms come up with self-regulatory guidelines after court, government raise quality concerns 

Some e-diagnostic companies act only as aggregators for multiple laboratories; others are merely technology platforms for self-operated medical laboratories.   

Dr Lal Pathlab – Suburban Diagnostic deal - a marriage made in a Petri dish

Inorganic growth in this sector has been the norm across the globe, and most countries in the developed world have 5-6 large players dominating the space

The revolution in DIY testing that will outlive the pandemic

The pandemic has radically changed the face of diagnostics, bringing testing into the home in a way many public health officials never imagined possible

Emerging healthcare trends put diagnostics sector in a sweet spot, IIFL Sec recommends buy on Metropolis, Thyrocare

Larger players from the diagnostic sector are positioned to gain more than the smaller ones and fragmented market share is an opportunity for them to expand their share.

This micro-cap emerges at the frontline in the battle against COVID-19

Foray into medical devices and the current ICMR approval for COVID-19 testing kit major positives

Decent Q3 show from Hester Biosciences despite drop in exports

Speaking to CNBC-TV18, Rajiv Gandhi, Chief Executive Officer and Managing Director of Hester Biosciences, said good sales of large animal vaccines and health products had helped the company achieve a net profit of 22 percent YoY.

Fortis Healthcare approves demerger of diagnostics business

Company's board approved a proposal to demerge its diagnostics business, including that housed in its subsidiary SRL Ltd into another majority-owned subsidiary, Fortis Malar Hospitals pursuant to a composite scheme of arrangement and amalgamation, Fortis Healthcare said in a regulatory filing.

Expect Dr Lal PathLabs to surpass industry growth in FY17: CEO

CEO Om Manchanda expects planned expansion of central lab network in Kolkata and Lucknow will help Dr Lal PathLabs to sustain margins in FY17. Diagnostics space which has low penetration in India makes it a good pitch for companies like Dr Lal PathLab, according to Citi's Prashant Nair.